Level Nine Sports, where families ski and ride...

 advertise with indeep media

There’s GOLD in Them There Hills, Termite Hills That Is…

Posted: December 19th, 2012 | Author: | Filed under: Entomology, Favorite New Thought, Geology, Outside the Box | Tags: , , , , , , | Comments Off on There’s GOLD in Them There Hills, Termite Hills That Is…

Cankler - Theres GOLD in Them There Hills, Termite Hills That Is - Litchfield NT Magnetic Termite MoundsThose superneat boffins at Australia’s science-factory – The CSIRO –  have found that termite mounds could indicate where gold or other mineral deposits lie beneath the surface.

Researchers believe that even small termite mounds could be reliable markers, and that termites themselves may be a cost-effective and environmentally friendly means of finding new mineral deposits.

Termite mounds are abundant across Australia’s north, and the largest ones can stand up to five metres tall. The research was published in science journals PLoS ONE and Geochemistry: Exploration, Environment, Analysis, found that at a test site in the West Australian goldfields termite mounds contained high concentrations of gold. This gold indicates there is a larger deposit underneath :: Read the full article »»»»

Early Promise For Human Embryonic Stem Cell Therapy

Posted: January 25th, 2012 | Author: | Filed under: Favorite New Thought, From The Web | Tags: , , , | Comments Off on Early Promise For Human Embryonic Stem Cell Therapy

Early promise for human embryonic stem cell therapyNature Blogs is reporting that 2 clinical trials testing retinal cells derived from human embryonic stem cells are showing positive preliminary results. A paper published in The Lancet says that the cells appear to be safe four months after being injected into the eyes of two blind patients and describes visual improvements in the patients.

This isn’t the first trial of therapies based on human embryonic stem cells, nor does it provide the first data on these therapies in humans. It does, however, provide the first — albeit early — data from the only ongoing clinical trial of such a treatment. One trial involves patients with ‘dry’ age-related macular degeneration – AMD – the leading cause of blindness in the developed world, whereas the other is focused a juvenile form of degenerative blindness called Stargardt’s macular dystrophy. Neither condition is treatable.

The reported results are from the first patient from each of the two trials, both of which will eventually enrol a dozen patients. Final results are expected in 2013. The early-stage safety trials are sponsored by Advanced Cell Technology, a stem-cell firm in Marlborough, Massachusetts (seeNever say die’, a recent News Feature about Advanced Cell Technology).

Read More at nature

Online Education Revolution, MITx

Posted: January 5th, 2012 | Author: | Filed under: Cankler Science News | Tags: , , , , , , , , | Comments Off on Online Education Revolution, MITx

In the world of Science and Technology three little letters on your resume can make all the difference, especially if those three letters are MIT.  Massachusetts Institute of Technology – MIT – is one of the worlds leading education institutions  that is also a powerhouse for research and development. Not only are MIT’s course subjects leading edge but the way courses are being delivered is going through an online revolutionary.

MIT’s latest education initiative, MITx isn’t just a platform to make their courses available online, they’ve been doing that for 10 years through the OpenCourseWare – OCW – program that has served over 2,100 courses to more than 100 million people world-wide. Instead MITx is a complete open source education platform. Other education institutions – public or private –  are free to join and integrate MITx into their own education platform.

“MIT has long believed that anyone in the world with the motivation and ability to engage MIT coursework should have the opportunity to attain the best MIT-based educational experience that Internet technology enables. OpenCourseWare’s great success signals high demand for MIT’s course content and propels us to advance beyond making content available. MIT now aspires to develop new approaches to online teaching.” said MIT President Susan Hockfield Read the full article »»»»

Higgs Boson: ‘The God Particle’ Nearly, But Not Quite!?

Posted: December 13th, 2011 | Author: | Filed under: Applied Science, Cankler Science News, Physics, Quantum Mechanics, Quantum Physics, Quantum Physics, Science News | Tags: , , , , , , , , , , , , , | Comments Off on Higgs Boson: ‘The God Particle’ Nearly, But Not Quite!?

Simulation - Higgs Event

Scientists at the European Organisation for Nuclear Research – CERN –  say they have found signs of – although not yet conclusively discovered – the Higgs boson, an elementary particle which is the missing link in the Standard Model of physics.

The famed particle is the missing link in current theories of physics, used to explain how everything gains its mass. Rumors have been crashing about the scientific community for weeks on these findings.

Fabiola Gianotti, the scientist in charge of the ATLAS experiment at the Large Hadron Collider, said the signal was centred at around 126 – GeV – Giga Electron Volts.

“I think it would be extremely kind of the Higgs boson to be here,” Gianotti told a seminar to discuss the findings :: Read the full article »»»»

Alzheimer’s Vaccine Closer

Posted: December 9th, 2011 | Author: | Filed under: Applied Science, Cankler Science News, Chemically Engineered, Medicated | Tags: , , , , , , , , , | Comments Off on Alzheimer’s Vaccine Closer

Alzheimer's Vaccine Closer

Scientists  have had success with a vaccine that could ultimately slow down advanced Alzheimer’s disease in humans. The team from Sydney University have published – PLoS ONE – details of a study which shows the vaccine slows one type of dementia by stopping neuro-fibre tangling.

Associate Professor Lars Ittner from Sydney University – Alzheimer’s and Parkinson’s Disease Laboratory says the study was conducted on mice that were already developing the condition. Ittner said it was the first time researchers had proved a vaccine that targeted the tau protien in mice that had already developed the disease. Read the full article »»»»